Syntara (ASX: SNT) — Company Overview, News & Financial Data
Syntara is a clinical-stage drug development company focused on developing therapies for blood cancers and conditions linked to inflammation and fibrosis.
Syntara
Syntara is a clinical-stage drug development company focused on developing therapies for blood cancers and conditions linked to inflammation and fibrosis. The company utilizes expertise in amine oxidase chemistry and extracellular matrix biology to discover and develop small-molecule therapeutics. Its lead clinical programs target haematological malignancies, including myelofibrosis and myelodysplastic syndrome, by inhibiting key enzymes responsible for tissue scarring and microenvironment dysfunction. Syntara also advances clinical and preclinical programs for skin scarring, pulmonary fibrosis, metabolic dysfunction-associated steatohepatitis, cardiac fibrosis, chronic kidney disease, and neuroinflammatory disorders such as Parkinson's disease in collaboration with research partners.
Snapshot
Operations
Products and/or services of Syntara
- Myelofibrosis Therapeutics: Clinical-stage development of oral small-molecule pan-LOX inhibitors targeting bone marrow fibrosis and disease progression in patients with myelofibrosis, evaluated in Phase 2 multinational clinical trials as monotherapy and combination therapy.
- Myelodysplastic Syndrome Therapeutics: Clinical-stage drug candidates undergoing Phase 1c/2 clinical trials for myelodysplastic syndrome, aiming to clear abnormal cells and restore normal blood cell production in patients affected by bone marrow failure and haematological malignancies.
- Skin Fibrosis and Scar Modification: Development of topical and oral amine oxidase inhibitors for scar prevention and skin fibrosis modification, evaluated through Phase 1c and Phase 2 clinical trials targeting burn scars, surgical scarring, and hypertrophic scar tissue formation.
- Neurodegenerative and Neuroinflammatory Therapies: Clinical-stage research and development of amine oxidase inhibitors targeting neuroinflammation, including clinical trials for Parkinson's disease conducted in partnership with international patient advocacy groups and academic research consortiums.
- Pulmonary and Cardiac Fibrosis Programs: Preclinical and early clinical-stage drug discovery programs developing targeted enzyme inhibitors for severe respiratory and cardiovascular diseases, including idiopathic pulmonary fibrosis and cardiac fibrosis caused by chronic inflammation.
- Metabolic and Renal Fibrosis Therapeutics: Research programs focused on small-molecule therapies targeting extracellular matrix dysfunction in metabolic dysfunction-associated steatohepatitis and chronic kidney disease, aimed at reducing tissue scarring and organ degradation.
Syntara executive team
- Gary Jonathan PhillipsCEO, MD & Director
- Wolfgang G. JarolimekHead of Drug Discovery
- Kristen MorganHead of Medical & Regulatory Affairs - Alliance Management
- Jana BaskarChief Medical Officer
- Timothy LuscombeCFO & Company Secretary
- Cameron David BillingsleyGeneral Counsel
- Dieter HamprechtHead of Chemistry
Recent announcements
What Syntara (SNT) has told the market, newest first.
- Investor Presentation Canaccord Drug & Device Conference
- Further significant results from SNT-4728 iRBD Phase 2 trialPrice sensitive
- Notification regarding unquoted securities - SNT
- Notification regarding unquoted securities - SNT
- Syntara expands SNT-9465 skin scarring studyPrice sensitive
Dividend history
Dividends per share paid by Syntara, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2022 | — | — | — | $1.7250 |
| FY2021 | — | — | — | $1.0790 |
| FY2004 | — | — | — | $0.0476 |
| FY2001 | — | — | — | $0.2185 |
| FY2000 | — | — | — | $0.0898 |
Key financials
Reported results for Syntara, in AUD.
- Market cap
- 35.4M
- Revenue (TTM)
- 6.9M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- -129.8%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 6.9M | -16.3M | -9M | |
| 7.3M | -22.1M | -7.9M | |
| 5.4M | -14.1M | -15.1M | |
| 5.8M | -18.7M | -11.4M |